Hämatologie und Onkologie 2 2017 23 4 European Medicines Agency Mee ting highlights from the Committee for Medicinal Products for Human Use CJMP 18 21 April 2017 http www ema europa eu ema index jsp curl pages news and events news 2017 04 news detail 002732 jsp mid WC0b01ac058004d5c1 5 Cohen S Kay J Biosimilars im plications for rheumatoid arthri tis therapy Curr Opin Rheumatol 29 260 268 2017 DOI 10 1097 BOR 0000000000000379 6 Vencovsky J et al A phase III ran domized double blind clinical stu dy comparing SB4 an etanercept biosimilar with etanercept reference product Enbrel in patients with moderate to severe rheumatoid ar thritis despite methotrexate therapy 52 week Results abstract Arthritis Rheumatol 2015 67 suppl 10 2015 7 Choe JY et al A randomised double blind phase III study comparing SB2 an infliximab biosimilar to the infli ximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methot rexate therapy Ann Rheum Dis 76 58 64 2017 DOI 10 1136 annrheum dis 2015 207764 8 Jørgensen K et al LB15 biosimilar infliximab CT P13 is not inferior to originator infliximab results from the 52 week randomized NOR SWITCH trial Abstract presented at the Uni ted European Gastroenterology UEG Week meeting 2016 15 19 October Vienna Austria 9 Tabernero J et al Biosimilars a po sition paper of the European Society for Medical Oncology with particular reference to oncology prescribers ESMO Open 1 e000142 2016 DOI DOI 10 1136 esmoopen 2016 000142 10 Jurczak W et al A phase III efficacy and safety study of the proposed ri tuximab biosimilar GP2013 versus rituximab in patients with previously untreated advanced follicular lym phoma ASH Annual Meeting San Diego USA 1809 2016 https ash confex com ash 2016 webprogram Paper89113 html 11 Coiffier B et al Pharmacokinetic and Safety of CT P10 a Biosimilar Can didate to the Rituximab Reference Product in Patients with Newly Diag nosed Advanced Stage Follicular Lym phoma AFL ASH Annual Meeting San Diego USA 1809 2016 https ash confex com ash 2016 webpro gram Paper89565 html 12 Rugo H et al Effect of a proposed tras tuzumab biosimilar compared with trastuzumab on overall response rate in Patients with ERBB2 HER2 positi ve metastatic breast cancer a rando mized clinical trial JAMA 317 37 47 2017 DOI 10 1001 jama 2016 18305 http jamanetwork com journals jama article abstract 2590051 13 http www biosimilarnews com pfi zer announces positive results from the reflections study for potential bio similar to herceptin trastuzumab 14 https www aerzteblatt de pdf 111 11 a452 pdf 15 Schwabe U Paffrath D Arzneiver ordnungs Report 2016 http www wido de fileadmin wido downloads pdf arzneimittel wido arz avr2016 pk 0916 pdf 16 Flume M Regional management of biosimilars in Germany GaBi Jour nal 5 125 127 2017 DOI http gabi journal net regional management of biosimilars in germany html 17 Freund M Rottmann M Wilhelm M Medikamentöse Tumortherapie An ordnung Durchführung und Nachsor ge Onkopedia 2012 https www onkopedia com de onkopedia guide lines medikamentoese tumorthera pie anordnung durchfuehrung und nachsorge view html index html 18 Frühe Nutzenbewertung neuer Arz neimittel in der Onkologie und Hä matologie 2011 2016 Analysen und Impulse Gesundheitspolitische Schriftenreihe der DGHO Band 10 2017 www erstehilfe krebs de Das Faltblatt Jung Krebs Erste Hilfe Tipps von Betroffenen steht bundesweit allen Interessierten zur Verfügung Bitte fordern Sie das Faltblatt an Deutsche Stiftung für junge Erwachsene mit Krebs Alexanderplatz 1 10178 Berlin Tel 030 28 09 30 56 0 Fax 030 28 09 30 56 9 www junge erwachsene mit krebs de info junge erwachsene mit krebs de

Hinweis: Dies ist eine maschinenlesbare No-Flash Ansicht.
Klicken Sie hier um zur Online-Version zu gelangen.